feedback

Course Director

Omid Hamid, MD
Omid Hamid, MD

The Angeles Clinic and Research Institute
Cedars Sinai Medical Care Foundation
Los Angeles, California

Faculty

Alexander M.M. Eggermont
Alexander M.M. Eggermont, MD, PhD

Gustave Roussy Comprehensive Cancer Center
Cancer Campus Grand Paris
Université Paris-Sud
Paris, France

Ahmad Tarhini
Ahmad Tarhini, MD, PhD

Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Jul-11
Expiration Date:2019-Jul-10
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, based on a live symposium held during the 2018 American Society of Clinical Oncology (ASCO) meeting, experts in the management of melanoma review the clinical experience with immunotherapy, opening with an assessment of the lessons learned from the use of immune-based options as a core treatment strategy in advanced disease. The experts will also discuss new developments in the use of immunotherapy, including evidence on checkpoint blockade as an adjuvant option in resectable melanoma. Throughout the activity, the faculty will offer thoughts on the future of checkpoint blockade in a range of melanoma treatment settings and discuss the clinical potential of newer combination strategies or sequential strategies that include immune-based treatment in patients with melanoma; the speakers will also review practical information such as appropriate dosing of immunotherapy and the management of immune-related adverse events.

Upon completion of this activity, participants should be better able to:

  • Cite the current therapeutic role of immune checkpoint inhibitors for the management of patients with advanced, unresectable melanoma
  • Summarize new evidence on the efficacy of checkpoint inhibitors as adjuvant therapy in resected, high-risk stage III disease
  • Select regimens with immunotherapy components for patients with unresectable metastatic or resectable stage III melanoma

Target Audience

This activity has been designed to meet the educational needs of oncologists, surgeons/surgical oncologists, dermatologists, and other professionals involved in the care of patients with melanoma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 11, 2018 - July 10, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months

Course Director and Moderator

Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute
Director of Experimental Therapeutics
Cedars Sinai Medical Care Foundation
Los Angeles, California

Omid Hamid, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Bristol-Myers Squibb; Celldex Therapeutics; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Immunocore; Incyte Corportation; MedImmune, LLC; Merck & Co., Inc.; Merck Serono; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Rinat. (Contracted Research for Institution)
Speakers Bureau participant with Amgen; Bristol-Myers Squibb; Genentech, Inc.; and Novartis Pharmaceuticals Corporation.
Advisory Board for Amgen; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.
Omid Hamid, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: pembrolizumab as adjuvant therapy in high-risk stage III melanoma; various combination strategies with checkpoint inhibitors and vaccine-based approaches/targeted agents.

Faculty

Alexander M.M. Eggermont, MD, PhD
Director General of Gustave Roussy Comprehensive Cancer Center
Cancer Campus Grand Paris
Professeur Oncologie, Université Paris-Sud
Paris, France

Alexander M.M. Eggermont, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Actelion Pharmaceuticals Ltd; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; HalioDx; Merck Sharp & Dohme Corp.; Merck Serono; Novartis AG; and Sanofi S.A.
Other Financial or Material Support from Novartis AG and Pfizer Inc. for Data and Safety Monitoring Board (DSMB).
Alexander M.M. Eggermont, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: pembrolizumab as adjuvant therapy in high-risk stage III melanoma; various combination strategies with checkpoint inhibitors and vaccine-based approaches/targeted agents.

Ahmad Tarhini, MD, PhD
Director, Melanoma and Skin Cancer Program
Director, Center for Immuno-Oncology Research
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Ahmad Tarhini, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Array BioPharma; Bristol-Myers Squibb; Huya Bioscience International; Incyte Corporation; Merck & Co., Inc.; NewLink Genetics Corporation; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals.
Ahmad Tarhini, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: pembrolizumab as adjuvant therapy in high-risk stage III melanoma; various combination strategies with checkpoint inhibitors and vaccine-based approaches/targeted agents.

CME Reviewer

Shaina Rozell, MD, MPH

Shaina Rozell, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.